T Cell News and Research

Latest T Cell News and Research

OMT announces new human antibody platform using genetically engineered rats expressing human antibodies

Open Monoclonal Technology, Inc. (OMT) today announced its new human antibody platform using the first genetically engineered rats expressing a human antibody repertoire. The company, which also created the first targeted knockout rats in 2009, is now cross-breeding the knockout animals with the rats expressing human antibodies to finalize its platform.

9 Dec 2010

Anchor Therapeutics announces publication describing pepducin technology as novel approach to target GPCR

Anchor Therapeutics today announced the publication of new research in the Proceedings of the National Academy of Sciences USA. The paper describes the identification and characterization of a pepducin-based allosteric agonist that targets CXCR4, a chemokine G protein-coupled receptor found on hematopoietic stem cells and other bone marrow-derived cells.

9 Dec 2010

Estrogen receptor beta inactivates critical genes, arrests cancer cell growth

Bionovo, today announced the publication of a study demonstrating that ERb causes cancer cell growth arrest by inactivating critical genes and enzymes responsible for cell growth. These results provide evidence that drugs that stimulate the production of or activate ERb are potential new therapies to prevent breast cancer.

9 Dec 2010

Organovo releases data on bioprinted blood vessels

Organovo, Inc., a regenerative medicine company focused on bioprinting technology, today announced the release of data on the first fully bioprinted blood vessels. Data was presented at the Tissue Engineering and Regenerative Medicine International Society (TERMIS) meeting in Orlando, Florida. The blood vessels were created through the use of the NovoGen MMX Bioprinter, Organovo's proprietary platform for the creation of 3D tissue constructs.

9 Dec 2010

Medulloblastoma subtypes are separate diseases with different origins

International effort led by St. Jude Children's Research Hospital scientists is expected to fuel development of targeted therapies and aid the search for unique combinations of cells and mutations that lead to other cancers.

8 Dec 2010

North Tees and Hartlepool NHS Foundation Trust pioneer novel technique for breast reconstruction

Surgeons at North Tees and Hartlepool NHS Foundation Trust are pioneering a novel technique for breast reconstruction that has the potential to make a huge difference to the lives of women affected by breast cancer.

8 Dec 2010

Low-dose diazepam with NS-398 combination has twice the neuroprotective effect of NS-398 alone

Status epilepticus, prolonged seizures, can lead to significant neurological deficits and, rarely, even death. The anticonvulsant diazepam, a first line therapy for the condition, is neuroprotective when administered in high doses within two hours from seizure onset. Researchers at the 64th AES Annual Meeting now report that the combination of low-dose diazepam and NS-398, a COX-2 inhibitor, has twice the neuroprotective effect of NS-398 alone.

8 Dec 2010

Small molecules show promise in protecting brain cells against nerve-degenerative diseases

Investigators at Southern Methodist University and The University of Texas at Dallas have discovered a family of small molecules that shows promise in protecting brain cells against nerve-degenerative diseases such as Parkinson's, Alzheimer's and Huntington's, which afflict millions.

8 Dec 2010

Bioengineers explain why some neurons die sooner than others in brains of AD patients

Bioengineers from the University of California, San Diego developed an explanation for why some types of neurons die sooner than others in the brains of people with Alzheimer's disease. These insights, published in the journal Nature Biotechnology on November 21, come from detailed models of brain energy metabolism developed in the Department of Bioengineering at the UC San Diego Jacobs School of Engineering.

8 Dec 2010

American Society for Microbiology honors UTHealth biologist for significant contributions

Known nationally for her research into single-cell organisms that affect oral health, Millicent "Mimi" Goldschmidt, Ph.D., a professor of microbiology and molecular genetics at The University of Texas Health Science Center at Houston (UTHealth), has been selected to receive the 2011 American Society for Microbiology (ASM) Founders Distinguished Service Award.

8 Dec 2010

SEEK reports Phase I safety trail for investigational flu vaccine

SEEK, a leading UK privately-owned drug-discovery group, today presented data on the successful conclusion of a Phase I safety and tolerability study for its investigational Universal Influenza Vaccine, FLU-v, at the World Influenza Congress in Amsterdam (7-9 December).

8 Dec 2010

New approach points towards effective stem cell therapies for spinal cord injury

Initial experiments suggest a possible new approach to stem cell therapy for spinal cord injuries—using biocompatible "channels" made of chitosan to guide regeneration of new spinal cord tissue, reports the December issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

8 Dec 2010

Shrink, EV Group enter development agreement for StemDisc stem cell and cell culturing platform

Shrink Nanotechnologies, Inc., an innovative nanotechnology company developing products and licensing opportunities in the solar energy industry, medical diagnostics and sensors and biotechnology research and development tools businesses, announced today that it has entered into a multi-year development and manufacturing agreement with EV Group, a 30 year old Austria-based leader in the nano-imprint lithography process designing and equipment manufacturing.

8 Dec 2010

Three abstracts on Defibrotide presented at ASH Annual Meeting

Gentium S.p.A. today announced that three abstracts on Defibrotide were presented at the 52nd Annual Meeting and Exposition of the American Society of Hematology held at the Orange County Convention Center in Orlando, Florida, December 4-7, 2010.

8 Dec 2010

Ultraviolet light activates enzyme that helps skin cancer cells survive, proliferate: Researchers

The sun's ultraviolet light activates an enzyme that helps skin cancer cells survive and proliferate, researchers report.

8 Dec 2010

Beike exits stem cell joint venture with SiriCell

Shenzhen Beike Biotechnology Co. Ltd. ("Beike") and SiriCell Technologies, Inc. announced that they are ending their partnership in "Beike Holdings Limited", a joint venture formed by the two companies in 2008. Going forward, Beike will exit the joint venture, and all current and future Beike Holdings-initiated business activities will operate exclusively under the SiriCell brand. Beike Holdings was established to expand the availability of Beike's stem cell products outside of China through collaborative hospital partnerships and new international subsidiaries.

8 Dec 2010

Case Western Reserve School of Medicine researchers receive NIH grant for four research endeavors

Case Western Reserve University School of Medicine faculty members are reaping the rewards of funding from the National Institutes of Health, in the form of grants and contracts. The funding totals more than $6.4 million for four different research endeavors.

8 Dec 2010

Immunomedics reports CD22 antibody produced significant anti-tumor response

Immunomedics, a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that epratuzumab, the Company's humanized anti-CD22 antibody, conjugated with SN-38, the active component of irinotecan, produced significant anti-tumor responses in a mouse model of human lymphoma.

8 Dec 2010

New technique may help develop novel treatments for brain diseases

Scientists have created a way to isolate neural stem cells - cells that give rise to all the cell types of the brain - from human brain tissue with unprecedented precision, an important step toward developing new treatments for conditions of the nervous system, like Parkinson's and Huntington's diseases and spinal cord injury.

8 Dec 2010

Positive data from Celator's CPX-351 Phase 2 study in newly-diagnosed AML presented at 52nd ASH

Celator Pharmaceuticals today announced positive clinical data in elderly patients with newly-diagnosed acute myeloid leukemia (AML) treated with CPX-351 (Cytarabine:Daunorubicin) Liposome Injection. Data were presented from the podium at the 52nd American Society of Hematology (ASH) Annual Meeting in Orlando, Florida.

8 Dec 2010

T Cell News and Research

Latest T Cell News and Research

OMT announces new human antibody platform using genetically engineered rats expressing human antibodies

Anchor Therapeutics announces publication describing pepducin technology as novel approach to target GPCR

Estrogen receptor beta inactivates critical genes, arrests cancer cell growth

Organovo releases data on bioprinted blood vessels

Medulloblastoma subtypes are separate diseases with different origins

North Tees and Hartlepool NHS Foundation Trust pioneer novel technique for breast reconstruction

Low-dose diazepam with NS-398 combination has twice the neuroprotective effect of NS-398 alone

Small molecules show promise in protecting brain cells against nerve-degenerative diseases

Bioengineers explain why some neurons die sooner than others in brains of AD patients

American Society for Microbiology honors UTHealth biologist for significant contributions

SEEK reports Phase I safety trail for investigational flu vaccine

New approach points towards effective stem cell therapies for spinal cord injury

Shrink, EV Group enter development agreement for StemDisc stem cell and cell culturing platform

Three abstracts on Defibrotide presented at ASH Annual Meeting

Ultraviolet light activates enzyme that helps skin cancer cells survive, proliferate: Researchers

Beike exits stem cell joint venture with SiriCell

Case Western Reserve School of Medicine researchers receive NIH grant for four research endeavors

Immunomedics reports CD22 antibody produced significant anti-tumor response

New technique may help develop novel treatments for brain diseases

Positive data from Celator's CPX-351 Phase 2 study in newly-diagnosed AML presented at 52nd ASH

Immunology eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Newsletters you may be interested in